TITLE

Anticoagulant Options � Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

AUTHOR(S)
Beasley, B. Nhi; Unger, Ellis F.; Temple, Robert
PUB. DATE
May 2011
SOURCE
New England Journal of Medicine;5/12/2011, Vol. 364 Issue 19, p1788
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors explain the reason behind the U.S. Food and Drug Administration's (FDA) approval of a higher dose of the anticoagulant, dabigatran, for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. They stress that their study do not support the strategy of transitioning patients to the lower dose if they have a bleeding episode while receiving the higher dose. They also point out that their decision was based on pharmacokinetic and pharmacodynamic modeling and not on efficacy and safety data.
ACCESSION #
60596247

 

Related Articles

  • Phenylpropanolamine and hemorrhagic stroke in women. Farquhar, Donald // CMAJ: Canadian Medical Association Journal;3/06/2001, Vol. 164 Issue 5, p684 

    Reports on a study of a link between phenylpropanolamine (PPA) and hemorrhagic stroke in men and women between the ages of 18 and 49. Background; Design; Conclusion; Decision of the United States Food and Drug Administration to remove PPA from all drug products.

  • Rivaroxaban (Xarelto) for Prevention of Thromboembolic Events. Erlich, Deborah R. // American Family Physician;10/15/2012, Vol. 86 Issue 8, p768 

    The article evaluates the Xarelto-branded rivaroxaban anticoagulant drug, which was approved by the U.S. Food and Drug Administration (FDA).

  • FDA Actions: New Oral Antiplatelet Agent.  // Critical Care Alert;Sep2009 Pharmacology, p1 

    The article reports that prasugrel, an oral antiplatelet agent in preventing thrombosis in patients with acute coronary syndrome, has been approved by the Food and Drug Administration (FDA).

  • FDA actions.  // Neurology Alert;Aug2012, Vol. 30 Issue 12, p2 

    The article focuses on the opinions issued by the U.S. Food and Drug Administration (FDA) on the anticoagulants rivaroxaban and apixaban.

  • FDA actions.  // OB/GYN Clinical Alert;Aug2012 Pharmacology Watch, p2 

    The article offers information regarding the rejection of application of two oral anticoagulants including rivaroxaban and apixaban by the U.S. Food and Drug Association.

  • Warfarin-replacement market prepares itself for Eliquis. D. W. // Medical Marketing & Media;Feb2013, Vol. 48 Issue 2, p17 

    The article reports on the eliquis drug which is a more preferred anticoagulant than Warfarin, in which approved by the U.S. Food and Drug Administration (FDA) on December 2012.

  • Pradaxa is facing another round of FDA scrutiny. McCaffrey, Kevin // Medical Marketing & Media;Feb2014, Vol. 49 Issue 2, p10 

    The article reports that blood-thinner Pradaxa may face a scrutiny by the U.S. Food and Drug Administration (FDA).

  • Research Replication. Drazen, Jeffrey M. // New England Journal of Medicine;11/23/2006, Vol. 355 Issue 21, p2252 

    The article presents an editorial looking at the risks connected to use of aprotinin. The article refers to the article "Observational studies of drug safety--aprotinin and the absence of transparency," by W. R. Hiatt, published in this issue. The author examines why the U.S. Food & Drug...

  • Apixaban reduced risk for stroke, embolism in patients ineligible for vitamin K antagonist. Smith, Wade S.; Furie, Bruce // Hem/Onc Today;5/25/2011, Vol. 12 Issue 10, p34 

    The article discusses a study funded by Bristol-Myers Squibb and Pfizer which showed that apixaban reduced the risk for stroke or systemic embolism without simultaneously increasing risk for major bleeding in patients ineligible for vitamin K antagonist.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics